RESUMEN
Cardiac sarcoidosis is an unpredictable, rare and potentially lethal condition whereby patients are exposed to sudden cardiac death. However, despite sophisticated imaging techniques and the need for careful multidisciplinary team assessment and management, the contribution from genetic mutations is uncertain. Hence, the case describes a novel observation of a patient who possessed both a filamin C mutation and cardiac sarcoidosis. The case highlights the need for detailed dedicated investigation and highlights the need for the consideration of genetic screening within patients with cardiac sarcoidosis.
Asunto(s)
Cardiomiopatías , Sarcoidosis , Disfunción Ventricular Izquierda , Humanos , Cardiomiopatías/complicaciones , Cardiomiopatías/genética , Cardiomiopatías/diagnóstico , Filaminas/genética , Pronóstico , Sarcoidosis/complicaciones , Sarcoidosis/genética , Sarcoidosis/diagnóstico , Disfunción Ventricular Izquierda/diagnóstico por imagen , Muerte Súbita Cardíaca/prevención & control , MutaciónRESUMEN
BACKGROUND: Chemotherapy-induced cardiotoxicity has become a prevalent complication. Regular monitoring of patients who received chemotherapy using 3D strain parameters may aid in early detection of myocardial damage and its prevention. The purpose of this study was to evaluate the effectiveness of three-dimensional speckle tracking imaging (3D-STI) in diagnosing and predicting the likelihood of cardiotoxicity. This was achieved by conducting a systematic review of original research articles. OBJECTIVES: To evaluate the role of 3D speckle tracking echocardiography in early detection of cardiotoxicity. METHODS: Relevant case control studies published prior to December 2022 were extracted to assess cardiotoxicity by 3D STE in patients after chemotherapy. RESULTS: A total of 1991 chemotherapy treated patients and control patients were included in the present review via pooling 22 studies. CONCLUSIONS: 3D speckle tracking echocardiography has the utility of non-invasive and objective evaluation of changes in left ventricular function in cancer patients undergoing chemotherapy. ROSPERO REGISTRATION NO: Study ID, CRD42023383790 on PROSPERO: International prospective register of systematic reviews.
